{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Joyce RP"],"funding":["NIAID NIH HHS","Division of Intramural Research, National Institute of Allergy and Infectious Diseases"],"pagination":["1637-1646"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9425786"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(10)"],"pubmed_abstract":["The rapid development of effective vaccines to combat the SARS-CoV-2 virus has been an effective counter measure to decrease hospitalization and the mortality rate in many countries. However, with the risk of mutated strains decreasing the efficacy of the vaccine, there has been an increasing demand for antivirals to treat COVID-19. While antivirals, such as remdesivir, have had some success treating COVID-19 patients in hospital settings, there is a need for orally bioavailable, cost-effective antivirals that can be administered in outpatient settings to minimize COVID-19-related hospitalizations and death. Nirmatrelvir (PF-07321332) is an orally bioavailable M<sup>pro</sup> (also called 3CL<sup>pro</sup>) inhibitor developed by Pfizer. It is administered in combination with ritonavir, a "],"journal":["Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents"],"pubmed_title":["The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations."],"pmcid":["PMC9425786"],"funding_grant_id":["R01 AI147325","AI158775","R01 AI158775","R01 AI157046"],"pubmed_authors":["Hu VW","Wang J","Joyce RP"],"additional_accession":[]},"is_claimable":false,"name":"The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations.","description":"The rapid development of effective vaccines to combat the SARS-CoV-2 virus has been an effective counter measure to decrease hospitalization and the mortality rate in many countries. However, with the risk of mutated strains decreasing the efficacy of the vaccine, there has been an increasing demand for antivirals to treat COVID-19. While antivirals, such as remdesivir, have had some success treating COVID-19 patients in hospital settings, there is a need for orally bioavailable, cost-effective antivirals that can be administered in outpatient settings to minimize COVID-19-related hospitalizations and death. Nirmatrelvir (PF-07321332) is an orally bioavailable M<sup>pro</sup> (also called 3CL<sup>pro</sup>) inhibitor developed by Pfizer. It is administered in combination with ritonavir, a ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-18T18:43:13.041Z","creation":"2025-02-19T03:29:12.025Z"},"accession":"S-EPMC9425786","cross_references":{"pubmed":["36060104"],"doi":["10.1007/s00044-022-02951-6"]}}